Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹85.99
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹434.96M
Enterprise Value₹2.05K
Total Cash (Recent Filing)₹7.01M
Total Debt (Recent Filing)₹1.05B
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.05
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Chemicals NicheSpecialization in organic intermediates for pharma, food & beverage and industrial users provides structural demand durability and customer stickiness. Niche products create higher technical barriers to entry and diversified end-market exposure, reducing single-market dependency over months.
Proven Profitability In Better YearsHistorical ability to deliver profits and operating cash flow in prior years demonstrates operational capability and a playbook for recovery. This track record supports the view that margins and cash generation can be restored with volume recovery or cost control, a durable positive for turnaround prospects.
Sizeable Asset Base & Positive EquityMaterial assets and positive equity provide a financial buffer to absorb cyclical shocks, enable refinancing or asset-backed funding, and preserve going-concern options. This balance-sheet scale supports longer-term operational continuity during a multi-quarter recovery.
Bears Say
Sharp Profitability DeclineA large FY2026 loss and negative operating margins indicate structural margin pressure or demand weakness that can persist absent meaningful operational changes. Sustained losses erode retained earnings and limit capacity to reinvest, increasing the risk of prolonged underperformance over several quarters.
Rising Leverage Reduces FlexibilityA material increase in debt-to-equity tightens financial flexibility, raises interest expense burden, and limits capacity for capex or working capital relief. If cash generation remains weak, higher leverage elevates refinancing and solvency risk over the medium term, pressuring strategic options.
Weak, Inconsistent Cash GenerationNegative OCF and deeply negative FCF signal that core operations are not funding the business, increasing reliance on external financing. Historical inconsistency in cash generation raises execution and refinancing risk, making it harder to sustain investment or manage debt over coming quarters.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹85.99 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹434.96M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 3 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on May 14, 2026. The company reported -₹8.48 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹8.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.311%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―